ArriVent BioPharma is exploding higher today as investors appear to be recalibrating following the sharp selloff earlier this week. The stock had previously cratered to a 52-week low after the company announced on October 6 that its Phase 3 FURVENT trial for firmonertinib failed to meet its primary endpoint in first-line EGFR exon 20 insertion mutant NSCLC. This clinical setback, which triggered a surge in trading volume to 14.10 million shares and prompted a pending shareholder investigation, had pushed the shares down to the $12.00 level before today's recovery.